Regenxbio has promoted Curran Simpson, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024.
 
Meanwhile, Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and is taking on an expanded role on the Board as Chairman.
 
In connection with these changes, Board member Daniel Tassé has been appointed as Regenxbio’s Lead Independent Director, a role previously held by Jerry Karabelas, Ph.D. Karabelas and Co-Founder Allan Fox will remain on the Board.

About New President & CEO Curran Simpson

Simpson is a seasoned biopharmaceuticals leader with over 35 years of industry experience. As the Chief Operating Officer (COO) at Regenxbio since January 2023, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations.
 
Simpson joined Regenxbio in 2015 and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining Regenxbio, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Simpson earlier served as interim CEO at Human Genome Sciences (HGS), where he led the integration of HGS into GSK.
 
“I am honored to serve as Regenxbio’s next President and CEO,” said Simpson. “I have been a part of shaping and leading our programs from preclinical to pivotal stages with Ken, and today, our AAV Therapeutics platform is well-positioned to make a meaningful impact. I look forward to our exciting next chapter as I continue to work with Ken and the rest of Regenxbio’s seasoned management team and Board to further advance our pipeline, drive the commercialization and scale of our business and deliver value for patients, shareholders and our other stakeholders.”
 
“Leading Regenxbio since our founding in 2009 has been a privilege,” said Mills. “As we advance our pivotal stage clinical trials, approach commercialization and prepare for our next chapter, now is the right time to transition leadership. Curran and I have worked closely together over the last nine years, and I am confident he brings the R&D, operational, and industry expertise to build on our momentum. I am enthusiastic about the future of Regenxbio and excited to continue partnering with Curran and working alongside the Board in my role as Chairman.”